QWQiong Wang

Qiong Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qiong Wang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Michael Betenbaugh

    Department of Chemical and Biomolecular Engineering Johns Hopkins University Baltimore Maryland USA

    5 shared publications
  • Shuang Yang

    Center for Clinical Mass Spectrometry, College of Pharmaceutical Sciences, Soochow University, Suzhou, China

    4 shared publications
  • Tiexin Wang

    Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland 21210, United States

    4 shared publications
  • John F. Cipollo

    Division of Bacterial, Parasitic and Allergenic Products (DBPAP), Laboratory for Bacterial Polysaccharides, Center for Biologics Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA

    3 shared publications
  • Cheng‐Yu Chung

    Department of Chemical and Biomolecular Engineering Johns Hopkins University Baltimore Maryland USA

    2 shared publications
  • Rong-Fong Shen

    Facility for Biotechnology Resources, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, United States

    2 shared publications

Latest Publications

  • Comprehensive N- and O-Glycoproteomic Analysis of Multiple Chinese Hamster Ovary Host Cell Lines

    by Qiong Wang, Tiexin Wang, Wells W. Wu, Chang-Yi Lin, Shuang Yang, Ganglong Yang, Ewa Jankowska, Yifeng Hu, Rong-Fong Shen, Michael J. Betenbaugh, et al.

    Glycoproteomic analysis of three Chinese hamster ovary (CHO) suspension host cell lines (CHO-K1, CHO-S, and CHO-Pro5) commonly utilized in biopharmaceutical settings for recombinant protein production is reported. Intracellular and secreted glycoproteins were examined. We utilized an immobilization and chemoenzymatic strategy in our analysis. Glycoproteins or glycopeptides were first immobilized through reductive amination, and the sialyl moieties were amidated for protection. The desired N- or O-glycans and glycopeptides were released from the immobilization resin by enzymatic or chemical digestion. Glycopeptides were studied by Orbitrap Liquid chromatography-mass spectrometry (LC/MS), and the released glycans were analyzed by Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF). Differences were detected in the relative abundances of N- and O-glycopeptide types, their resident and released glycans, and their glycoprotein complexity. Ontogeny analysis revealed key differences in features, such as general metabolic and biosynthetic pathways, including glycosylation systems, as well as distributions in cellular compartments. Host cell lines and subfraction differences were observed in both N- and O-glycan and glycoprotein pools. Differences were observed in sialyl and fucosyl glycan distributions. Key differences were also observed among glycoproteins that are problematic contaminants in recombinant antibody production. The differences revealed in this study should inform the choice of cell lines best suited for a particular bioproduction application.


  • Acute Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Pregnancy Is Associated with Placental Angiotensin-Converting Enzyme 2 Shedding

    by Elizabeth S. Taglauer, Elisha M. Wachman, Lillian Juttukonda, Timothy Klouda, Jiwon Kim, Qiong Wang, Asuka Ishiyama, David J. Hackam, Ke Yuan, Hongpeng Jia


  • The interplay of protein engineering and glycoengineering to fine‐tune antibody glycosylation and its impact on effector functions

    by Qiong Wang, Tiexin Wang, Roushu Zhang, Shuang Yang, Kevin S. McFarland, Cheng‐Yu Chung, Hongpeng Jia, Lai‐Xi Wang, John F. Cipollo, Michael J. Betenbaugh

    The N‐glycan pattern of an IgG antibody, attached at a conserved site within the fragment crystallizable (Fc) region, is a critical antibody quality attribute whose structural variability can also impact antibody function. For tailoring the Fc glycoprofile, glycoengineering in cell lines as well as Fc amino acid mutations have been applied. Multiple glycoengineered Chinese hamster ovary cell lines were generated, including defucosylated (FUT8KO), α‐2,6‐sialylated (ST6KI), and defucosylated α‐2,6‐sialylated (FUT8KOST6KI), expressing either a wild‐type anti‐CD20 IgG (WT) or phenylalanine to alanine (F241A) mutant. Matrix‐assisted laser desorption ionization‐time of flight mass spectrometry characterization of antibody N‐glycans revealed that the F241A mutation significantly increased galactosylation and sialylation content and glycan branching. Furthermore, overexpression of recombinant human α‐2,6‐sialyltransferase resulted in a predominance of α‐2,6‐sialylation rather than α‐2,3‐sialylation for both WT and heavily sialylated F241A antibody N‐glycans. Interestingly, knocking out α‐1,6‐fucosyltransferase (FUT8KO), which removed core fucose, lowered the content of N‐glycans with terminal Gal and increased levels of terminal GlcNAc and Man5 groups on WT antibody. Further complement‐dependent cytotoxicity (CDC) analysis revealed that, regardless of the production cells, WT antibody samples have higher cytotoxic CDC activity with more exposed Gal residues compared to their individual F241A mutants. However, the FUT8KO WT antibody, with a large fraction of bi‐GlcNAc structures (G0), displayed the lowest CDC activity of all WT antibody samples. Furthermore, for the F241A mutants, a higher CDC activity was observed for α‐2,6‐ compared to α‐2,3‐sialylation. Antibody‐dependent cellular cytotoxicity (ADCC) analysis revealed that the defucosylated WT and F241A mutants showed enhanced in vitro ADCC performance compared to their fucosylated counterparts, with the defucosylated WT antibodies displaying the highest overall ADCC activity, regardless of sialic acid substitution. Moreover, the FcγRIIIA receptor binding by antibodies did not always correspond directly with ADCC result. This study demonstrates that glycoengineering and protein engineering can both promote and inhibit antibody effector functions and represent practical approaches for varying glycan composition and functionalities during antibody development.


  • Metabolic engineering challenges of extending N-glycan pathways in Chinese hamster ovary cells

    by Qiong Wang, Tiexin Wang, Shuang Yang, Sha Sha, Wells W. Wu, Yiqun Chen, Jackson T. Paul, Rong-Fong Shen, John F. Cipollo, Michael J. Betenbaugh


  • The impact of sialylation linkage‐type on the pharmacokinetics of recombinant butyrylcholinesterases

    by Cheng‐Yu Chung, Qiong Wang, Shuang Yang, Sandra Chough, Younji Seo, John F. Cipollo, Joseph P. Balthasar, Michael J. Betenbaugh

    Chinese Hamster Ovary (CHO) cells typically produce glycoproteins with N‐glycans terminating in α‐2,3 sialylation. Human cells produce glycoproteins that include α‐2,3 and α‐2,6 sialic acids. In order to examine the impact of altering protein sialylation on pharmacokinetic properties, recombinant human butyrylcholinesterase (BChE) was produced in CHO cells by knocking out the α‐2,3 sialyltransferase genes followed by overexpression of the α‐2,6 sialyltransferase (26BChE) enzyme. The N‐glycan composition of 26BChE was compared to BChE with α‐2,3 sialylation (23BChE) derived from wild‐type CHO cells. Both 23BChE and 26BChE exhibited comparable antennarity distributions with bi‐antennary di‐sialylated glycans representing the most abundant glycoform. CD‐1 mice were intravenously injected with the 23BChE or 26BChE, and residual BChE activities from blood collected at various time points for pharmacokinetic analyses. Although 23BChE contained a slightly lower initial sialylation level compared to 26BChE, the molecule exhibited higher residual activity between 5 to 24 hours post‐injection. Pharmacokinetic analyses indicated that 23BChE exhibited an increase in area under the curve (AUC) and a lower volume of distribution at steady‐state than that of 26BChE. These findings suggest that the type of sialylation linkage may play a significant role in the pharmacokinetic behavior of a biotherapeutic when tested in in vivo animal models.


  • Open Access

    Characterization of intact glycopeptides reveals the impact of culture media on site‐specific glycosylation of EPO‐Fc fusion protein generated by CHO‐GS cells

    by Qiong Wang, Ganglong Yang, Tiexin Wang, Weiming Yang, Michael J. Betenbaugh, Hui Zhang

    With the increasing demand to provide more detailed quality attributes, more sophisticated glycan analysis tools are highly desirable for biopharmaceutical manufacturing. Here, we performed an intact glycopeptide analysis method to simultaneously analyze the site‐specific N‐ and O‐glycan profiles of the recombinant erythropoietin Fc (EPO‐Fc) protein secreted from a Chinese hamster ovary glutamine synthetase stable cell line and compared the effects of two commercial culture media, EX‐CELL (EX) and immediate advantage (IA) media, on the glycosylation profile of the target protein. EPO‐Fc, containing the Fc region of immunoglobulin G1 (IgG1) fused to EPO, was harvested at Day 5 and 8 of a batch cell culture process followed by purification and N‐ and O‐glycopeptide profiling. A mixed anion exchange chromatographic column was implemented to capture and enrich N‐linked glycopeptides. Using intact glycopeptide characterization, the EPO‐Fc was observed to maintain their individual EPO and Fc N‐glycan characteristics in which the EPO region presented bi‐, tri‐, and tetra‐branched N‐glycan structures, while the Fc N‐glycan displayed mostly biantennary glycans. EPO‐Fc protein generated in EX medium produced more complex tetra‐antennary N‐glycans at each of the three EPO N‐sites while IA medium resulted in a greater fraction of bi‐ and tri‐antennary N‐glycans at these same sites. Interestingly, the sialylation content decreased from sites 1–4 in both media while the fucosylation progressively increased with a maximum at the final IgG Fc site. Moreover, we observed that low amounts of Neu5Gc were detected and the content increased at the later sampling time in both EX and IA media. For O‐glycopeptides, both media produced predominantly three structures, N1F1F0SOG0, N1H1F0S1G0, and N1H1F0S2G0, with lesser amounts of other structures. This intact glycopeptide method can decipher site‐specific glycosylation profile and provide a more detailed characterization of N‐ and O‐glycans present for enhanced understanding of the key product quality attributes such as media on recombinant proteins of biotechnology interest.